Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032662 · ClinicalTrials.gov registry record · Phase 2
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT07032662 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 162 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07032662, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
Florida
- Site Number - 1603 - Maitland
- Site Number - 1606 - Miami
- Site Number - 1617 - Ormond Beach
- Site Number - 1620 - Port Charlotte
- Site Number - 1633 - Rockledge
California
- Site Number - 1618 - Carlsbad
- Site Number - 1619 - Orange
- Site Number - 1607 - Rancho Mirage
- Site Number -1608 - San Francisco
District of Columbia
- Site Number - 1630 - Washington D.C.
- Site Number - 1601 - Washington D.C.
Massachusetts
- Site Number - 1623 - Boston
- Site Number - 1625 - Worcester
Arizona
- Site Number - 1612 - Tucson
Colorado
- Site Number - 1626 - Parker
Connecticut
- Site Number - 1621 - New Haven
Kansas
- Site Number - 1602 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07032662
The ClinicalTrials.gov registry entry for NCT07032662 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (11% higher). The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07032662 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07032662 about?
NCT07032662 is a clinical study titled "IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
What is the current status of trial NCT07032662?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2025-03-18. Estimated completion is 2030-05.
What conditions does trial NCT07032662 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT07032662?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT07032662?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07032662 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.